Tremendous progress marked to-date in more effectively training and harnessing the immune system to recognize, hone in on, and destruct cancer cells has evidenced the promise and power of immune-oncology and in so doing, ushered in an exciting suite of novel immuontherapeutics; the advent of immune-based approaches against cancer.
Despite these important advances, translational researchers, physician-scientists, and clinicians in oncology, must collectively up the tempo by more precisely developing this powerful anti-cancer weaponry to better control the immune system and ultimately achieve higher response rates across tumour types. To deliver on these ambitions, oncology professionals must continue to collaborate together, rapidly exchange and debate insights from the bench-bedside and back again, and accelerate efforts aimed at overcoming the major obstacles that are currently standing in our way.
Bringing the very latest discovery in the field of cancer immunotherapy to Barcelona, 09 – 11 October 2017, Defence is the Best Attack – Immuno-Oncology Breakthroughs, this EACR program incorporating a trio of keynotes to be delivered by Jedd Wolchok (Memorial Sloan Kettering Cancer Centre – MSKCC, New York, USA), Lisa Coussens (OHSU Knight Cancer Institute, Portland, USA) and Carl June (Perelman School of Medicine, University of Pennsylvania, USA), will attract basic and translational scientists and clinicians for an exploration, debate and exchange of data covering timely topics including immune checkpoints, immune-editing, innate immune response, microbioma and the immune system, CAR T cells, vaccination, biomarkers of response to immunotherapy, and mechanisms of resistance to immunotherapy.
“This exceptional EACR meeting, taking place in Gaudí´s stunning Casa Milà, Barcelona, represents an essential platform for this must-have sharing of avant-garde discovery in the rapidly emerging field of cancer immunology. More specifically, our cherry-picked panel of outstanding, internationally renowned speakers will discuss and explore their up-to-the-minute findings as well as roadmap the ´where to´ in identifying novel targets, progressing our understanding of the mechanisms of action of therapeutic interventions, developing improved biomarkers of response to therapy, and overcoming mechanisms of intrinsic and acquired resistance to immunotherapy,” comments Joan Seoane, Director of Translational Research at VHIO and Chair of this forthcoming EACR conference alongside the three other Conference Committee members: Johanna Joyce (Ludwig Institute for Cancer Research/University of Lausanne, Switzerland), Ignacio Melero (Clinical University of Navarra, Spain), Daniel Peeper (Netherlands Cancer Institute – NKI, The Netherlands).
“In short, EACR´s Defence is the Best Attack, is set to track the latest breakthroughs in immuno-oncology as well as signpost future next steps.” he concludes.
To discover the many reasons for joining some of the world´s most recognized trailblazers in immune-oncology this coming autumn, submit an abstract before the deadline of 31 July, and secure your place by registering before 01 September 2017 visit:
